Role of the transcriptional coactivators YAP/TAZ in liver cancer

El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 Llovet, 2016, Hepatocellular carcinoma, Nat Rev Dis Primers, 2, 16018, 10.1038/nrdp.2016.18 Farazi, 2006, Hepatocellular carcinoma pathogenesis: from genes to environment, Nat Rev Cancer, 6, 674, 10.1038/nrc1934 Johnson, 2014, The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment, Nat Rev Drug Discov, 13, 63, 10.1038/nrd4161 Patel, 2017, Hippo signaling in the liver regulates organ size, cell fate, and carcinogenesis, Gastroenterology, 152, 533, 10.1053/j.gastro.2016.10.047 Pan, 2010, The hippo signaling pathway in development and cancer, Dev Cell, 19, 491, 10.1016/j.devcel.2010.09.011 Lee, 2010, The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis, Proc Natl Acad Sci U S A, 107, 8248, 10.1073/pnas.0912203107 Lu, 2010, Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver, Proc Natl Acad Sci U S A, 107, 1437, 10.1073/pnas.0911427107 Zhang, 2010, The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals, Dev Cell, 19, 27, 10.1016/j.devcel.2010.06.015 Zhou, 2009, Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene, Cancer Cell, 16, 425, 10.1016/j.ccr.2009.09.026 Song, 2010, Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression, Proc Natl Acad Sci U S A, 107, 1431, 10.1073/pnas.0911409107 Overholtzer, 2006, Transforming properties of YAP, a candidate oncogene on the chromosome 11q amplicon, Proc Natl Acad Sci U S A, 103, 12405, 10.1073/pnas.0605579103 Tao, 2014, Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice, Gastroenterology, 147, 690, 10.1053/j.gastro.2014.05.004 Zhang, 2012, Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells, Hepatology, 56, 2051, 10.1002/hep.25899 Wu, 2013, The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense, Cell Rep, 3, 1663, 10.1016/j.celrep.2013.04.020 Camargo, 2007, YAP1 increases organ size and expands undifferentiated progenitor cells, Curr Biol, 17, 2054, 10.1016/j.cub.2007.10.039 Dong, 2007, Elucidation of a universal size-control mechanism in Drosophila and mammals, Cell, 130, 1120, 10.1016/j.cell.2007.07.019 Danovi, 2008, Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis, Cell Death Differ, 15, 217, 10.1038/sj.cdd.4402226 Konsavage, 2012, Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells, J Biol Chem, 287, 11730, 10.1074/jbc.M111.327767 Teng, 2017, Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice, J Pathol, 241, 463, 10.1002/path.4850 Liu, 2010, MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties, Biochem Biophys Res Commun, 394, 623, 10.1016/j.bbrc.2010.03.036 Chen, 2018, miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression, EBioMedicine, 35, 142, 10.1016/j.ebiom.2018.08.010 Zhao, 2010, A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP), Genes Dev, 24, 72, 10.1101/gad.1843810 Zhang, 2017, The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis, Nat Commun, 8 Hata, 2012, A novel acetylation cycle of transcription co-activator Yes-associated protein that is downstream of Hippo pathway is triggered in response to SN2 alkylating agents, J Biol Chem, 287, 22089, 10.1074/jbc.M111.334714 Mao, 2014, SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma, Oncogene, 33, 1468, 10.1038/onc.2013.88 Fang, 2018, SET1A-mediated mono-methylation at K342 regulates YAP activation by blocking its nuclear export and promotes tumorigenesis, Cancer Cell, 34, 103, 10.1016/j.ccell.2018.06.002 Jeong, 2018, Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer, J Clin Invest, 128, 1010, 10.1172/JCI95802 Kim, 2017, Hippo signaling interactions with Wnt/beta-catenin and Notch signaling repress liver tumorigenesis, J Clin Invest, 127, 137, 10.1172/JCI88486 He, 2011, NF-kappaB and STAT3 – key players in liver inflammation and cancer, Cell Res, 21, 159, 10.1038/cr.2010.183 Geisler, 2015, Emerging roles of Notch signaling in liver disease, Hepatology, 61, 382, 10.1002/hep.27268 Aylon, 2016, The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation, Genes Dev, 30, 786, 10.1101/gad.274167.115 Ye, 2017, JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity, Cancer Res, 77, 5287, 10.1158/0008-5472.CAN-17-0229 He, 2010, The critical role of AKT2 in hepatic steatosis induced by PTEN loss, Am J Pathol, 176, 2302, 10.2353/ajpath.2010.090931 Kodama, 2018, Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis, Proc Natl Acad Sci U S A, 115, E10417, 10.1073/pnas.1808968115 Yuan, 2018, NUAK2 is a critical YAP target in liver cancer, Nat Commun, 9, 10.1038/s41467-018-07394-5 Wu, 2015, Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis, Nat Commun, 6 Takamura, 2011, Autophagy-deficient mice develop multiple liver tumors, Genes Dev, 25, 795, 10.1101/gad.2016211 Lee, 2018, Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap, Nat Commun, 9, 10.1038/s41467-018-07338-z Carter, 2006, A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers, Nat Genet, 38, 1043, 10.1038/ng1861 Thompson, 2008, Examining the link between chromosomal instability and aneuploidy in human cells, J Cell Biol, 180, 665, 10.1083/jcb.200712029 Ganem, 2014, Cytokinesis failure triggers hippo tumor suppressor pathway activation, Cell, 158, 833, 10.1016/j.cell.2014.06.029 Aylon, 2006, A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization, Genes Dev, 20, 2687, 10.1101/gad.1447006 Iida, 2004, Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function, Oncogene, 23, 5266, 10.1038/sj.onc.1207623 Zhang, 2017, Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2, Cancer Cell, 31, 669, 10.1016/j.ccell.2017.04.004 Weiler, 2017, Induction of chromosome instability by activation of yes-associated protein and forkhead box m1 in liver cancer, Gastroenterology, 152, 2037, 10.1053/j.gastro.2017.02.018 Rizvi, 2018, YAP-associated chromosomal instability and cholangiocarcinoma in mice, Oncotarget, 9, 5892, 10.18632/oncotarget.23638 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Plouffe, 2016, Characterization of Hippo pathway components by gene inactivation, Mol Cell, 64, 993, 10.1016/j.molcel.2016.10.034 Cosset, 2017, Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma, Cancer Cell, 32, 856, 10.1016/j.ccell.2017.10.016 Chen, 2018, High mobility group protein B1 controls liver cancer initiation through yes-associated protein dependent aerobic glycolysis, Hepatology, 67, 1823, 10.1002/hep.29663 Mosseri, 2000, Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phoshatase and phosphoenolpyruvate carboxykinase, Metabolism, 49, 321, 10.1016/S0026-0495(00)90132-X Wu, 2016, Paternal psychological stress reprograms hepatic gluconeogenesis in offspring, Cell Metab, 23, 735, 10.1016/j.cmet.2016.01.014 Hu, 2017, YAP suppresses gluconeogenic gene expression through PGC1alpha, Hepatology, 66, 2029, 10.1002/hep.29373 Cox, 2016, Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth, Nat Cell Biol, 18, 886, 10.1038/ncb3389 Cox, 2018, Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth, EMBO J, 37, 10.15252/embj.2018100294 Du, 2018, Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells, Gastroenterology, 154, 1465, 10.1053/j.gastro.2017.12.022 Ma, 2018, Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells, Science, 360, 10.1126/science.aan5931 Huang, 2006, Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration, Science, 312, 233, 10.1126/science.1121435 Anakk, 2013, Bile acids activate YAP to promote liver carcinogenesis, Cell Rep, 5, 1060, 10.1016/j.celrep.2013.10.030 Cheng, 2018, S1P stimulates proliferation by upregulating CTGF expression through S1PR2-mediated YAP activation, Mol Cancer Res, 16, 1543, 10.1158/1541-7786.MCR-17-0681 Ji, 2019, FGF15 activates Hippo signaling to suppress bile acid metabolism and liver tumorigenesis, Dev Cell, 48, 460, 10.1016/j.devcel.2018.12.021 Lee, 2019, Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation, Science, 363, 644, 10.1126/science.aav0173 Devisscher, 2016, The role of macrophages in obesity-driven chronic liver disease, J Leukoc Biol, 99, 693, 10.1189/jlb.5RU0116-016R Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 Li, 2015, STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma, J Clin Invest, 125, 4239, 10.1172/JCI81203 Guo, 2017, Single tumor- initiating cells evade immune clearance by recruiting type II macrophages, Genes Dev, 31, 247, 10.1101/gad.294348.116 Kim, 2018, Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma, Gut, 67, 1692, 10.1136/gutjnl-2017-314061 Hagenbeek, 2018, The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors, Sci Signal, 11, 10.1126/scisignal.aaj1757 Jiao, 2014, A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer, Cancer Cell, 25, 166, 10.1016/j.ccr.2014.01.010 Liu-Chittenden, 2012, Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP, Genes Dev, 26, 1300, 10.1101/gad.192856.112